Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02331251 · ClinicalTrials.gov registry record · Phase 1
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
A Phase 1 study, sponsored by Western Regional Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT02331251: Clinical Trial Phase 1 study, sponsored by Western Regional Medical Center.
NCT02331251 is a Phase 1 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02331251, a Phase 1 study, was terminated before completion, sponsored by Western Regional Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
The Phase Ib and II cohorts will enroll patients with metistatic solid tumors. Phase II only will enroll the following patients: Patients with metastatic sarcoma to be enrolled in the following 4 arms: pembro plus gemcitabine, pembro plus gemcitabine and docetaxel, pembro plus gemcitabine and vinorelbine, and pembro plus liposomal doxorubicin. Patients with metastatic pancreatic adenocarcinoma to be enrolled in the pembro plus gemcitabine and nab-paclitaxel arm. Patients with extensive-stage small cell lung cancer to be enrolled in the pembro plus irinotecan arm. Patients with ER+ breast cancer to be enrolled in the pembro and vinorelbine arm. Patients with ovarian cancer to be enrolled in the pembroplus liposomal doxorubicin arm. Patients with metastatic TNBC (ER/PR/HER2 negative) to be enrolled in the pembro plus gemcitabine arm.
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Vinorelbine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02331251
The ClinicalTrials.gov registry entry for NCT02331251 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Western Regional Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT02331251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02331251 about?
NCT02331251 is a clinical study titled "Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)". The Phase Ib and II cohorts will enroll patients with metistatic solid tumors. Phase II only will enroll the following patients: Patients with metastatic sarcoma to be enrolled in the following 4 arms: pembro plus gemcitabine, pembro plus gemcitabine and docetaxel, pembro plus gemcitabine and vino...
What is the current status of trial NCT02331251?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2014-12. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02331251?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Vinorelbine (DRUG).
Who is sponsoring clinical trial NCT02331251?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.